title: Prognostic Biomarkers for Hodgkin Lymphoma.
abstract: The prognosis of patients with classical Hodgkin lymphoma following chemo- and radiotherapy has been excellent during the last 4 decades. However, the development of secondary malignancies is of major concern. Therefore, the reduction of radiotherapy application is a major objective of ongoing clinical trials. De-escalation of treatment may increase the risk of relapses and thus may lead to reappearance of prognostic factors. Prognostic biomarkers might help to identify patients who are at increased risk of relapse. This review summarizes the current knowledge about potential prognostic biomarkers for patients with classical Hodgkin lymphoma.
authors.affiliation: a Department of Pediatrics , Martin Luther University Halle-Wittenberg , Halle , Germany.
authors.forename: Martin S
authors.initials: MS
authors.lastname: Staege
authors.affiliation: a Department of Pediatrics , Martin Luther University Halle-Wittenberg , Halle , Germany.
authors.forename: Stefanie
authors.initials: S
authors.lastname: Kewitz
authors.affiliation: a Department of Pediatrics , Martin Luther University Halle-Wittenberg , Halle , Germany.
authors.forename: Toralf
authors.initials: T
authors.lastname: Bernig
authors.affiliation: a Department of Pediatrics , Martin Luther University Halle-Wittenberg , Halle , Germany.
authors.forename: Caspar
authors.initials: C
authors.lastname: Kühnöl
authors.affiliation: a Department of Pediatrics , Martin Luther University Halle-Wittenberg , Halle , Germany.
authors.forename: Christine
authors.initials: C
authors.lastname: Mauz-Körholz
mesh_terms: D014408:Biomarkers, Tumor / Q000378:metabolism*; D006689:Hodgkin Disease / Q000175:diagnosis* / Q000378:metabolism* / Q000628:therapy*; D006801:Humans; D011379:Prognosis; D012008:Recurrence
chemical_list: D014408:Biomarkers, Tumor
keywords: Hodgkin lymphoma; gene expression; prognostic factors; therapy resistance